Physician profile
Scott Lieberman
NPI 1134412760
$3,882.00
in general payments reported to CMS, 2019-2025
20 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.05 · 2021: $11.56 · 2022: $239 · 2023: $825 · 2024: $693 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.51 |
| Education | $323.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $972.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $475.88 | 2024-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $299.73 | 2023-2025 | Glassia |
| Astrazeneca Pharmaceuticals Lp | $295.26 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Insmed, INC. | $280.04 | 2022-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $266.18 | 2025 | Dupixent |
| Verona Pharma, INC. | $245.02 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $199.52 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $158.99 | 2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $129.84 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Genzyme Corporation | $114.40 | 2025 | |
| Lilly USA, LLC | $90.12 | 2025 | Zepbound, Mounjaro |
| Melinta Therapeutics, LLC | $84.65 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Abbvie INC. | $73.73 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.47 | 2022-2025 | Ofev, Jascayd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $55.89 | 2024-2025 | Fetroja |
| Inspire Medical Systems, INC. | $34.64 | 2025 | Inspire |
| Baxter Healthcare | $26.25 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $17.03 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.